UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
July 23 2021 - 8:00AM
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology
company developing therapeutics to slow, halt, or reverse diseases
of aging, today announced that it will host a webcast for investors
and analysts on July 27, 2021 at 8:00 a.m. Pacific Time (11:00 a.m.
Eastern Time) to discuss clinical data from the Phase 1 study in
diabetic macular edema (DME) and wet age-related macular
degeneration (AMD) patients treated with a single injection of
UBX1325.
At this webcast, Robert Bhisitkul, M.D., Ph.D.,
professor of ophthalmology and director of the Retina Fellowship at
University of California, San Francisco, and members of UNITY
senior management will present on recent safety and initial
efficacy signals from UBX1325, including rapid improvements in
best-corrected visual acuity (BCVA), central subfield thickness
(CST), and sub- and intra-retinal fluid (SRF, IRF) – all key
clinical measures of disease progression, observed in a majority of
trial subjects.
“As we announced on July 6, UBX1325 had a
favorable safety and tolerability profile and we saw improvements
in vision and retinal structure in patients treated with UBX1325 in
our Phase 1 study,” said Anirvan Ghosh, Ph.D., chief executive
officer of UNITY. “We look forward to having Dr. Bhisitkul share
his insights and observations following the review of patient data
and images. We are excited to continue exploring this novel
senolytic mechanism in DME and wet AMD patients as a potential
disease-modifying alternative and complement to anti-VEGF
treatments.”
Based on previous data announced, UNITY is
currently enrolling additional patients with advanced wet AMD in
the Phase 1 study to gather additional data to support a potential
Phase 2a study in wet AMD. A parallel Phase 2a study in DME is
currently enrolling, with information about that trial available
here.
Conference Call
InformationUNITY will host a conference call and webcast
for investors and analysts on Tuesday, July 27, 2021, at 8:00 a.m.
PT (11:00 a.m. ET) to discuss the UBX1325 clinical data. The live
webcast can be accessed in the “Investors and Media” section of our
website, www.unitybiotechnology.com, under “Events &
Presentations” or by clicking here. You may also listen to the
call by dialing (877) 235-8637 within the U.S. or (704)
815-6400 outside the U.S. and providing conference ID
7296381. A replay will be available two hours after the completion
of the call and can be accessed in the “Investors & Media”
section of our website, under “Events and
Presentations.” About UBX1325UBX1325
is an investigational compound being studied for age-related
diseases of the eye, including diabetic macular edema (DME),
age-related macular degeneration (AMD), and diabetic retinopathy
that is not approved for any use in any country. UBX1325 is a
potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2
family of apoptosis regulating proteins. UBX1325 is designed to
inhibit the function of proteins that senescent cells rely on for
survival. In preclinical studies, UNITY has demonstrated that
targeting Bcl-xL with UBX1325 preferentially eliminated senescent
cells from diseased tissue while sparing cells in healthy tissue.
UNITY’s goal with UBX1325 is to transformationally improve
real-world outcomes for patients with DR, DME, and AMD.
About UNITYUNITY is developing
a new class of therapeutics to slow, halt, or reverse diseases of
aging. UNITY’s current focus is on creating medicines to
selectively eliminate or modulate senescent cells and thereby
provide transformative benefit
in age-related ophthalmologic and neurologic diseases.
More information is available
at www.unitybiotechnology.com or follow us
on Twitter and LinkedIn.
Forward-Looking StatementsThis
press release contains forward-looking statements including
statements related to UNITY’s understanding of cellular senescence
and the role it plays in diseases of aging, the potential for UNITY
to develop therapeutics to slow, halt, or reverse diseases of
aging, including for ophthalmologic and neurologic diseases, our
expectations regarding potential benefits, activity, effectiveness,
and safety of UBX1325, the potential for UNITY to successfully
commence and complete clinical studies of UBX1325 for DME, AMD, and
other ophthalmologic diseases, the expected timing of results of
our studies of UBX1325, the timing of the expected commencement,
progression, and conclusion of our studies including those of
UBX1325, and UNITY’s expectations regarding the sufficiency of its
cash runway. These statements involve substantial known and unknown
risks, uncertainties, and other factors that may cause our actual
results, levels of activity, performance, or achievements to be
materially different from the information expressed or implied by
these forward-looking statements, including the risk that
the COVID-19 worldwide pandemic may continue to
negatively impact the development of preclinical and clinical drug
candidates, including delaying or disrupting the enrollment of
patients in clinical trials, risks relating to the uncertainties
inherent in the drug development process, and risks relating to
UNITY’s understanding of senescence biology. We may not actually
achieve the plans, intentions, or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions, and expectations
disclosed in the forward-looking statements we make. The
forward-looking statements in this press release represent our
views as of the date of this release. We anticipate that subsequent
events and developments will cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we have no current intention of doing so
except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this release. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of UNITY in general, see UNITY’s most
recent Quarterly Report on Form 10-Q for the quarter
ended March 31, 2021, filed with the Securities and
Exchange Commission on May 11, 2021, as well as other
documents that may be filed by UNITY from time to time with
the Securities and Exchange Commission.
Media
Canale Communications
Jason Spark
Jason.spark@canalecomm.com
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Apr 2023 to Apr 2024